Dr. Danielle Townsley, MD, MSc, Executive Director of Precision Medicine, TA Head, Oncology, Global Development since December 2024.

Dr. Townsley is the head of the Oncology Therapeutic Area at Amgen, and partners with cross functional leaders across R&D to guide the strategy and execution of translational, reverse translational, and precision medicine strategies for which she and her team are ultimately accountable.

Danielle brings an excellent balance of robust clinical development experience and deep translational scientific acumen to the role. Danielle was formerly an Executive Medical Director and Group Leader in Early Development Oncology at Amgen. She has over 15 years of drug development experience and currently leads the Product Team for AMG 193, a MTA-cooperative PRMT5 inhibitor. Formerly, she led teams for AMG 199, AMG 427, and AMG 176.

Before joining the pharmaceutical industry, Danielle worked at the NIH’s National Heart, Lung, and Blood Institute for 7 years on investigator-initiated, translational Ph1/2 studies of novel hematopoietic and immune therapies for hematologic disorders.   In the industry, she’s driven strategic development of early-stage oncology assets, including antibody-drug conjugates, immuno-oncology, cell therapy, T cell engagers, and small molecules.